Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at

Research analysts at assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Trading Down 4.1 %

NBRV stock opened at $1.65 on Thursday. The company has a market cap of $52.82 million, a P/E ratio of -0.09 and a beta of 1.56. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45. The company has a quick ratio of 0.78, a current ratio of 1.13 and a debt-to-equity ratio of 0.12. The business has a fifty day moving average of $1.66 and a 200-day moving average of $1.78.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last released its quarterly earnings data on Monday, April 17th. The biotechnology company reported ($7.77) EPS for the quarter. The company had revenue of $10.57 million during the quarter. Nabriva Therapeutics had a negative net margin of 148.11% and a negative return on equity of 255.35%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nabriva Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,294 shares of the biotechnology company’s stock, valued at approximately $41,000. Susquehanna International Group LLP owned about 0.07% of Nabriva Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.23% of the company’s stock.

About Nabriva Therapeutics

(Get Rating)

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Read More

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.